Small biotech whiffs bad­ly in PhI­II pan­cre­at­ic can­cer study, prompt­ing halt of an­oth­er late-stage tri­al

A few months af­ter back­flip­ping on­to Nas­daq in a strate­gic merg­er, Rafael Hold­ings is learn­ing first­hand the draw­backs of be­com­ing a pub­lic com­pa­ny.

The New …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER